Platelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target.
about
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceOral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Platelet physiology and antiplatelet agents.Lack of effect of nitrates on exercise stress test results in patients with microvascular angina.
P2860
Platelet hyperaggregability: impaired responsiveness to nitric oxide ("platelet NO resistance") as a therapeutic target.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Platelet hyperaggregability: i ...... nce") as a therapeutic target.
@en
Platelet hyperaggregability: impaired responsiveness to nitric oxide
@nl
type
label
Platelet hyperaggregability: i ...... nce") as a therapeutic target.
@en
Platelet hyperaggregability: impaired responsiveness to nitric oxide
@nl
prefLabel
Platelet hyperaggregability: i ...... nce") as a therapeutic target.
@en
Platelet hyperaggregability: impaired responsiveness to nitric oxide
@nl
P2860
P1476
Platelet hyperaggregability: i ...... nce") as a therapeutic target.
@en
P2093
Sharmalar Rajendran
Yuliy Y Chirkov
P2860
P304
P356
10.1007/S10557-008-6098-7
P577
2008-03-11T00:00:00Z